IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced that it has
commenced a registered underwritten public offering of $50 million of
shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole underwriter for the
Aerie intends to use the net proceeds of the offering for general
corporate purposes, including the complete funding of RhopressaTM commercialization
costs, execution of clinical trials in Japan, commencement of
construction of a manufacturing plant in Ireland and continuation of
preclinical activity in support of its product pipeline, along with
ongoing working capital requirements.
A shelf registration statement relating to the shares is effective with
the Securities and Exchange Commission. The shares may be offered only
by means of a prospectus, including a prospectus supplement, forming a
part of the effective registration statement. A preliminary prospectus
supplement related to the offering will be filed with the Securities and
Exchange Commission today. An electronic copy of the preliminary
prospectus supplement and the accompanying prospectus relating to the
offering will be available on the website of the Securities and Exchange
Commission at www.sec.gov.
Copies of the preliminary prospectus supplement and the final prospectus
supplement, when available, and the accompanying prospectus relating to
the offering may be obtained by contacting Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Ave., 5th Floor, New York, New York
10022, or by telephone at 212-829-7122, or by e-mail at email@example.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Aerie, and shall not
constitute an offer, solicitation or sale of any security in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two lead product candidates are once-daiIy IOP-lowering
therapies with novel mechanisms of action to treat patients with
glaucoma or ocular hypertension. The NDA filing for RhopressaTM (netarsudil
ophthalmic solution) 0.02% was submitted in the third quarter of 2016.
The second product candidate, RoclatanTM (netarsudil/latanoprost
ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of
RhopressaTM and widely prescribed PGA latanoprost, currently
has two Phase 3 registration trials underway, named Mercury 1 and
Mercury 2. If these trials are successful, a RoclatanTM NDA
filing is expected to take place near year-end 2017. Aerie is also
focused on the development of additional product candidates and
technologies in ophthalmology.
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should," "exploring," "pursuing" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the
success, timing and cost of our ongoing and anticipated preclinical
studies and clinical trials for our current product candidates,
including statements regarding the timing of initiation and completion
of the studies and trials; our expectations regarding the clinical
effectiveness of our product candidates and results of our clinical
trials; the timing of and our ability to request, obtain and maintain
U.S. Food and Drug Administration or other regulatory authority approval
of, or other action with respect to, our product candidates; our
expectations regarding the commercialization of our product candidates;
our expectations related to the offering discussed in this press
release, including the use of proceeds from the offering; the potential
advantages of our product candidates; and our plans to pursue
development of our product candidates for additional indications and
other therapeutic opportunities. By their nature, forward-looking
statements involve risks and uncertainties because they relate to
events, competitive dynamics and industry change, and depend on
regulatory approvals and economic circumstances that may or may not
occur in the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under the
heading "Risk Factors" in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ materially
from the forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160915006512/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media